Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has received a consensus rating of "Buy" from the seven brokerages that are presently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $25.60.

Several equities analysts have recently commented on the company. HC Wainwright restated a "buy" rating and issued a $47.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th.

Stoke Therapeutics Stock Up 2.2 %

Shares of STOK opened at $9.25 on Friday. The business has a 50-day simple moving average of $8.03 and a two-hundred day simple moving average of $10.06. Stoke Therapeutics has a 52 week low of $5.35 and a 52 week high of $17.58. The stock has a market cap of $505.02 million, a price-to-earnings ratio of -4.40 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. On average, equities analysts anticipate that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now owns 63,962 shares of the company's stock, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the firm's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares of the company's stock, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,532 shares of company stock worth $143,332 over the last 90 days. 11.30% of the stock is owned by insiders.

Institutional Trading of Stoke Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Toronto Dominion Bank purchased a new stake in shares of Stoke Therapeutics in the fourth quarter worth approximately $35,001,000. RTW Investments LP increased its stake in Stoke Therapeutics by 10.1% in the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock worth $56,512,000 after purchasing an additional 471,240 shares during the period. Norges Bank bought a new stake in shares of Stoke Therapeutics during the fourth quarter worth $3,472,000. Tang Capital Management LLC purchased a new stake in shares of Stoke Therapeutics during the fourth quarter valued at $3,309,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Stoke Therapeutics in the fourth quarter worth about $3,218,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.